GFP Adeno-Associated Virus ( AAV-MSSDP )

Adeno-associated viruses (AAVs) are non-pathogenic, helper-dependent parvoviruses with a 4.7 kb single-stranded DNA genome. The icosahedral (T=1) virion shell is 25 nm in diameter and contains 60 viral capsid protein (VP) subunits. The amino acid residue clusters, interlaced loops, surface topology, and three-dimensional structure of different AAV capsids determine their biological properties for entry into host cells and the tissue tropism they exhibit in different hosts. Since the discovery of the first AAV strain (AAV2) in the 1960s, several other serotypes and new AAV variants have been isolated. Naturally occurring AAV isolates exhibit different tissue tropisms in different hosts. Certain AAV strains have been reported to have particularly potent cardiac transduction abilities. Successful applications of these AAV strains in preclinical and clinical settings continue to be reported, with a focus on the treatment of cardiovascular diseases. Adeno-associated virus with GFP (AAV-MSSDP) is a dedicated reporter gene AAV that has undergone significant capsid engineering and modification. Designed for targeted gene delivery, the virus possesses an engineered capsid derived from AAV serotype 2 (AAV2). Specifically, the capsid of AAV2 has been modified by the insertion of the peptide sequence MSSDPRRPPRDG at position I588. This innovative modification confers the virus with enhanced capabilities, specifically targeting cardiomyocytes (precursor cells of the heart muscle), making it a powerful tool for cardiovascular research and gene therapy.